研究显示,新治疗的obe-cel在77%的B细胞ALL复发的成年人中实现了缓解. New treatment obe-cel achieves remission in 77% of adults with recurrent B-cell ALL, study shows.

《新英格兰医学杂志》的一项新研究表明,所谓的 " obe-cel " 治疗可以帮助成人患一种被称为 " B细胞ALL " 的血癌,这种血癌已经恢复或抵抗了以前的治疗。 A new study in the New England Journal of Medicine shows that a treatment called obe-cel can help adults with a type of blood cancer called B-cell ALL that has returned or resisted previous treatments. 在该项研究中,77%的病人获得了缓解,反应平均持续14.1个月。 In the study, 77% of patients achieved remission, with responses lasting an average of 14.1 months. 虽然像细胞释放综合征这样的副作用很常见,但严重的副作用很少见,使Aobe-cel为这些病人提供了有希望的选择。 While side effects like cytokine release syndrome were common, serious side effects were rare, making obe-cel a promising option for these patients.